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 Drug susceptible tuberculosis program in the Forest Region, Republic of Guinea. 
 The WHO goal of 90% treatment success remains elusive in rural areas. 
 TB-HIV coinfection remains a major risk factor for low treatment success.  
















OBJECTIVES: To analyze the treatment success rate (TSR = sum of cured or 
treatment completed) in the tuberculosis (TB) program for drug susceptible TB (DS-
TB) of the “Centre Hospitalier Régional Spécialisé” in Macenta, Forest Region, 
Republic of Guinea. 
METHODS: This cohort study included patients starting treatment for DS-TB between 
2010 and 2017. Data collection was part of the documentation for the national TB 
program. Descriptive analysis was applied to determine TSR in various patient 
groups. Further, we performed logistic regression to determine factors influencing 
TSR, in new and relapse cases versus all other previously treated cases. A subgroup 
analysis for only microbiologically confirmed pulmonary TB was added.  
RESULTS: We included 3,969 patients. TSR increased from 68.3% in 2010 to 80.8% 
in 2017 (p<0.001). Mortality (11.2%) occurred mainly in early treatment months, while 
loss to follow-up (5.9%) increased towards later treatment months. Risk factors for 
low TSR were advanced age, positive HIV status, long travel distances (>100km) to 
the clinic and late drug refill. 
CONCLUSION: TSR in the Forest Region of Guinea remains below the WHO goal of 
90%. Reaching this target remains a challenge in rural areas with high early mortality 
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Introduction  
In recent years, tuberculosis (TB) was the 10th leading cause of death worldwide and 
the 7th leading in low-income countries (WHO 2016). In 2017, 25% (2.48 million) of 
the estimated 10 million cases developing active TB worldwide were estimated to live 
in the WHO African Region. To contain the TB epidemic, the WHO developed the 
“End TB” strategy in 2015, as part of the Sustainable Development Goals (Johnston 
2016). Compared to 2015, the final target of “END TB in 2035“ aims for ≥ 90% 
treatment success rate (TSR); a reduction by 95% in number of TB deaths, and a 
reduction of the TB incidence rate by 90% to ≤ 10 cases per 100’000 population per 
year (WHO 2015). 
TB incidence in the Republic of Guinea (from now on: Guinea) in 2017 was estimated 
at 176 cases per 100,000 population. Nationally in 2017, there were 13,752 new and 
relapse TB cases (incident cases) registered, of which 73% were bacteriologically 
confirmed and 83% knew their HIV status (WHO 2018a). Among these, 25% were 
TB-HIV co-infections. The people affected are around one third women (35%), a bit 
less than two third men (54%) and 11% children under 15 years (WHO 2018b). The 
proportion of TB-HIV co-infection is higher in the regions at the border with Sierra 
Leone and Côte d’Ivoire (Ministry of Health Guinea 2019).   
In 2017 in the WHO Africa Region, TSR reached 82% in incident cases, while Guinea 
reported 88% TSR in 2017 (WHO 2019). From internal analyses of the TB program in 











understand the TSR for the TB program in Macenta and potential reasons for the 
anticipated lower TSR.   
To our knowledge this is the first publication of TB data in Guinea outside of the 
aggregated national data. 
Objectives 
To understand TSR of people living with tuberculosis (PLTB) who are enrolled in the 
tuberculosis program for people with drug susceptible tuberculosis (DS-TB) at the 
“Centre Hospitalier Régional Spécialisé” (CHRS) in Macenta, we defined our 
objectives as follows:  
1. To characterize the total number of people with DS-TB starting anti-tuberculosis 
treatment (ATT) between 2010 and 2017 and to assess TSR according to 
treatment history. 
 
2. To assess the predictors for TSR in the following patient categories according to 
previous treatment history: a) in incident cases and b) in all other previously 
treated patients.  
 
Methodology 
Study design and setting 
This is a retrospective observational cohort study; we report according to the 
STROBE (checklist in supplements) statement (Von Elm et al. 2007). It was 
conducted in Macenta, 800km southeast of the capital Conakry. Macenta is the 











population of 1.6 million accounts for 15% of the population of Guinea (République 
de Guinée 2018).  
The CHRS is a national reference center for HIV, leprosy and TB, including 
multidrug- or rifampicin-resistant TB (MDR/RR-TB). The hospital is a public-private 
partnership between the Ministry of Health and Public Hygiene of Guinea and SAM 
global, a faith-based non-profit organization. Antiretroviral treatment (ART), leprosy 
treatment and ATT are free-of-charge for PLTB and provided to the CHRS by the 
respective national programs. 
We only included data from people with DS-TB, treated with category 1 (6 months, 
2HRZE/4HR)1 or 2 (prolonged to 8 months and including streptomycin, 
2HRZES/1HRZE/5HRE)1 regimens, and enrolled in the TB program at the CHRS 
between 01.01.2010 and 31.12.2017. PLTB were followed up until end of treatment, 
or until any other WHO TB outcome defined in the following sections was met, i.e. for 
a maximum of 8 months of treatment. The follow up for microbiologically confirmed 
pulmonary TB was performed by 3 sputum controls after ATT start, at month 2 (for 
category 1) respectively month 3 (for category 2) as well as at month 5 and at the 
end of treatment. There was no systematic follow-up plan in place during the study 
period, outcome data of patients lost to follow-up were partially retrieved from 
peripheral health posts during supervision visits. We analyzed outcomes per TB 
diagnosis – therefore some patients contributed more than 1 TB episode to the 
analysis.  
Clinical management of tuberculosis at the CHRS 
                                               










The ATT at the CHRS follows the national guidelines published by the “Programme 
National de Lutte Antituberculeuse” (PNLAT), based on the WHO recommendations 
(Ministry of Health Guinea 2019). Culture-based drug susceptibility testing was not 
available at the CHRS for the study period. Pulmonary TB (PTB) testing is performed 
by sputum microscopy (Ziehl-Neelsen staining). A chest x-ray supports the diagnosis 
of clinical PTB if sputum is not available or if sputum is negative while clinical 
suspicion is high. Extrapulmonary TB (EPTB) was mainly diagnosed clinically. Since 
November 2016, molecular testing with GeneXpert has been available with a higher 
sensitivity to detect Mycobacterium tuberculosis. GeneXpert based diagnostics were 
primarily reserved for people living with HIV (PLWH) with negative sputum 
microscopy. ATT follows the directly observed treatment strategy (DOTS) during the 
intensive phase. Newly diagnosed PLTB were tested for HIV and – in case of a 
positive result – started on ART within 2-8 weeks of starting ATT.  
Definitions and outcomes 
We applied the following WHO TB outcome definitions (WHO 2020): 
Cured: Bacteriologically confirmed TB at treatment start and smear- or culture-
negative in the last month of treatment and on at least one previous occasion. 
Treatment completed: Completed treatment without evidence of failure BUT with no 
record to show that sputum smear or culture results in the last month of treatment 
and on at least one previous occasion were negative. 
Treatment failed: Sputum smear or culture is positive at month 5 or later during 
treatment. 











Loss to follow-up (LTFU): No treatment started, or treatment interrupted for 2 
consecutive months or more.  
Not evaluated: No assigned treatment outcome, including cases “transferred out” to 
another treatment unit as well as cases for whom the treatment outcome is unknown 
to the reporting unit.  
Treatment success: Percentage of all PLTB declared “cured” or “treatment 
completed” 
We applied the following WHO TB case definitions (WHO 2020): 
Bacteriologically confirmed TB case: has a biological specimen that is positive by 
smear microscopy, culture or WHO approved rapid diagnostics. 
Clinically diagnosed TB case: does not fulfill the criteria for bacteriological 
confirmation but has been diagnosed with active TB by a clinician or other medical 
practitioner (including cases diagnosed on the basis of X-ray abnormalities or 
suggestive histology and extrapulmonary cases without laboratory confirmation).  
 
As a measure of the distance from home to the clinic, we calculated the kilometers by 
road, using Google maps. This is a simplification as river crossings and poor quality 
of roads can have a much larger impact on the actual travel time than the kilometers 
per se. Since exact addresses are inexistent, the nearest settlement was taken to 
measure distance within Guinea. For foreign nationals no exact address was 
reported, therefore they were classified as own group. As Ebola period we defined 
the main epidemic Ebola period in Macenta that lasted from August through 
December 2014. During this time, patient numbers declined considerably at the 











of 2013 (Leuenberger 2015). We suspected that treatment success might be 
substantially worse for PLTB enrolled during those months.   
Data collection 
Data were extracted from the CHRS electronic patient management system. It 
contains all items of the national documentation required by the PNLAT plus 
additional points relevant for management at the CHRS. We extracted data on age, 
sex, place of residence, year of registration, and clinical data relevant to TB and HIV 
status. 
Statistical analysis 
We used descriptive statistics to assess baseline characteristics of all patients 
starting ATT for drug-susceptible TB between 2010 - 2017. For continuous data we 
used summary statistics. The Mann-Whitney U test was used, verifying the non-
adherence of the data to the Gaussian distribution. In investigating the association 
between categorical variables, we used Pearson's chi-square test. In case of a cell 
count less than five, Fisher's exact test was performed.  
We stratified patients according to WHO TB categories in a) incident cases and in b) 
all other retreated patients.  
We used logistic regression to assess factors that might influence treatment success 
as defined according to our conceptual framework. These were the following 
variables: age in 10-year strata (following the WHO definitions), year of ATT start, 
sex, distance from the CHRS (grouped in Macenta town, distance from CHRS 
≤100km respectively >100km and neighbouring countries), Ebola period in Macenta, 











clinically diagnosed TB. All variables were included in the analysis, as all of them can 
have an effect as confounders. 
In a subgroup analysis we included only bacteriologically confirmed PTB to assess 
the program in the “true positive” TB cases. For this analysis we added an additional 
variable - late treatment refill - to assess whether this predicted treatment failure. Late 
treatment refill was defined as a microbiological control later than 2 months (for 
treatment category 1) or later than 3 months (for treatment category 2) after ATT 
start. This proxy was taken since refill dates were not systematically recorded. 
All statistical analyses were performed with Stata version 16.0. (StataCorp. 2019) 
Results 
4,089 PLTB were registered in the tuberculosis program between 2010 and 2017, of 
whom 2.9% (120) were people with MDR-TB and therefore excluded from our 
analysis. The remaining 3,969 people with DS-TB were included in the primary 
descriptive analysis. In the logistic regression analysis, 3,679 incident cases were 
included. Figure 1 shows the number of participants at each stage and where 
patients were excluded due to missing parameters.  
Figure 1: Flow diagram showing the numbers of participants at each stage. 
Legend figure1: TB – tuberculosis, PTB – pulmonary TB, LTFU – loss to follow up, 
NE – not evaluated. 
Objective 1: Patient characteristics and treatment success rates  
Overall, 2,517 (63.4%) male and 1,452 (36.6%) female patients – including 216 
(5.4%) children under 15 years – were treated (Table 1). One third (36.3%) were from 











countries. The TB characteristics and HIV status at ATT start are shown in Table 2. 
The key changes between the years 2010 and 2017 are the following: an increase 
from 36.0% up to 43.7% in patients coming from a distance of more than 100km; an 
increase of people tested for HIV from 75.6% up to 94.6%; an increase of PLWH on 
ART at ATT start from 20% up to 81.2%; and a decrease of bacteriologically 
confirmed TB cases from 70.1% down to 60.3%. 
Of the 3,969 patients treated within these eight years, 115 were treated twice and 
one patient was treated three times at the CHRS.  
Table 1: Patient demographics, including all patients diagnosed with a drug 
susceptible tuberculosis between 2010 and 2017 at the CHRS in Macenta.  
Legend table 1: Treatment success is defined as the sum of the category “cured” or 
the category “treatment completed”. Unfavorable treatment outcome includes all 
treatment outcomes other than treatment success. 
Table 2: Tuberculosis characteristics and HIV status at inclusion in TB program and 
diagnosed with drug susceptible tuberculosis between 2010 and 2017 at the CHRS 
in Macenta 
Legend table 2: Treatment success is defined as the sum of the category “cured” or 
the category “treatment completed”. Unfavorable treatment outcome includes all 
treatment outcomes other than treatment success. 
 
An overall TSR of 75.7% was achieved over these 8 years (75.5% for men and 
76.1% for women), with a clear increase from 68.3% in 2010 to 80.8% in 2017. 











defined as “not evaluated”, the remaining 3,815 patients reach a TSR of 78.4%. 
However, according to WHO outcome definitions, we kept patients transferred out in 
the outcome category “not evaluated”. Figure 2 shows TSR for each year. 
The success rate for incident cases was 76.3% (Figure 3Error! Reference source 
not found.) but only 67.1% for all other retreated cases. Figure 4 shows the strong 
negative impact of a positive HIV status on the TSR and Figure 5 shows the TSR for 
bacteriologically confirmed versus clinically diagnosed TB cases. 
Of the 443 (11.2%) patients who died during treatment, almost half (48.8%) died 
during the first month of treatment, 23.0% during the second and slightly more than 
25% in either month three or four of treatment. The number and proportion of LTFU 
(234, 5.9%) however increased over the duration of treatment: 23.1% of these 
occurred in the first two months and 55.6% after month three of treatment. 
Figure 2: Evolution of the treatment success rate 2010 - 2017 
Legend figure2: Treatment success rate, defined as the sum of categories “cured” or 
“treatment completed” in people diagnosed with drug susceptible tuberculosis, shown 
for all patients grouped by year of registration. The shaded bars show treatment 
success, while the filled bars show treatment outcomes with no treatment success.  
Percentages indicate the treatment success rate.  
Figure 3: Overall treatment success rate and stratified according to history of 
previous anti-tuberculosis treatment 
Legend figure3: Treatment success rate, defined as the sum of “cured” or “treatment 
completed”, in people diagnosed with drug susceptible tuberculosis, shown for all 
patients, incident cases (new and relapse cases) and all other retreated patients (all 











success, while the filled bars show treatment outcomes with no treatment success.  
Percentages indicate treatment success rate.  
Figure 4: Treatment success rate according to HIV status 
Legend figure 4: Treatment success rate, defined as the sum of “cured” or “treatment 
completed” in people diagnosed with drug susceptible TB, and shown for people not 
living with HIV versus people living with HIV on ART and not on ART at start of anti-
TB treatment. The shaded bars show treatment success, while the filled bars show 
treatment outcomes with no treatment success. Percentages indicate treatment 
success rate. TB – tuberculosis, ART – antiretroviral therapy 
Figure 5: Treatment success rate according to bacteriologically confirmed or clinically 
diagnosed TB cases  
Legend figure 5: Treatment success rate, defined as the sum of “cured” or “treatment 
completed” in people diagnosed with drug susceptible TB, and shown for 
bacteriologically confirmed TB and clinically diagnosed TB. The shaded bars show 
treatment success, while the filled bars show treatment outcomes with no treatment 
success. Percentages indicate treatment success rate. TB – tuberculosis 
Objective 2: factors associated with treatment success 
After excluding patients with missing data on treatment history, distance or type of TB 
disease (see table 3 in supplements) the remaining 3679 patients diagnosed with 
incident TB were included in the main logistic regression. Figure 6 shows the crude 
and adjusted odds ratio (OR) and confidence interval (CI) from logistic regression. 
After adjusting for the above-named factors, we showed that older patients have 
lower odds of treatment success than patients between 25 and 34 years of age 











for people coming from places >100km from the CHRS (OR 0.77, 95% CI 0.64 – 
0.93) compared to people coming from Macenta, PLWH on ART at start of ATT (OR 
0.34, 95% CI 0.27 – 0.43), PLWH not on ART at start of ATT (OR 0.27, 95% CI 0.20 
– 0.36) compared to people not living with HIV; as well as patients with clinically 
diagnosed TB (OR 0.81, 95% CI 0.66 – 1.00) as compared to patients with 
bacteriologically confirmed TB. Conversely, the odds of achieving treatment success 
increased by 8% per calendar year (OR 1.08, 95% CI 1.04 – 1.12). 
Figure 6: Crude and adjusted odds ratio (95% confidence interval and p-value) from 
logistic regression analysis identifying factors associated with treatment success in 
new and relapse TB cases  
Legend figure 6: Logistic regression for crude and adjusted odds ratio. OR – odds 
ratio, CI – confidence interval, TB – tuberculosis; CHRS - Centre Hospitalier Régional 
Spécialisé in Macenta; ART - antiretroviral therapy, Ebola - months of the main 
epidemic Ebola period in Macenta (August - December 2014); year of anti-TB 
treatment start refers to the years 2010-2017, the OR is given per later year of 
registration and compared to the respective previous year, for example treatment 
success of 2011 compared to 2010 and treatment success of 2012 compared to 
2011 etc. (Jann 2014) 
Logistic regression for all other retreated patients (excluding the relapse cases), 
showed fewer significant factors due to small numbers (n = 149).  
The subgroup analysis of microbiologically confirmed incident PTB cases, including 
2,082 patients with sputum results at predefined months, showed a lower TSR (OR 
0.50, 95% CI 0.35 – 0.71) in patients with late drug refill at month 2 respectively 3, 












We found an improvement of the overall TSR from 68.3% in 2010 to 80.8% in 2017. 
The WHO goal of 90% TSR was not reached due to 443 (11.2%) deaths, 234 (5.9%) 
LTFU and 158 (4.0%) patients without evaluated treatment outcome. The most 
significant risk factors for not achieving treatment success were a positive HIV status, 
older age and greater distance from home to the CHRS. 
Our data are generalizable for PLTB in Guinea, given a similar distribution of sex, 
age and clinical manifestation as depicted in the WHO tuberculosis profile of Guinea 
in 2017 (WHO 2018b). 
TB as a disease of poverty is reflected in the high early death rate in our population, 
reflecting late health-seeking behavior. Patients are diagnosed late, often after 
having tried out local remedies before consulting TB clinics since these often involve 
more financial investments due to longer travel times and higher costs for transport, 
food and lodging, even if basic diagnostics and treatment are free of charge. Other 
obstacles to early treatment are logistical challenges of the health care system (drug 
stock-outs / often long turn-around times for results). The WHO recommends 
integrated HIV and TB services with decentralized delivery of services for both 
infections (WHO 2015), but experience in Macenta shows that frequent stock-outs in 
smaller sites drive patients towards larger centers – at the cost of longer travel times 
and increased financial expenses for patients. This is seen in the increase of patients 
over time travelling from a distance of more than 100 km to reach the CHRS. 
TB-HIV co-infection proved to be a major detrimental factor for treatment success in 
our study. This stands in contrast to the WHO data for Guinea in 2017 that show an 











85% for PLWH in 2017 (WHO 2019). In our setting, patients were often diagnosed 
with HIV at the time of TB diagnosis (36.4% of our PLWH were not yet on ART at 
time of TB diagnosis); hence already presenting with an opportunistic infection and 
advanced immune deficiency. But not only the immune deficiency, also the pill 
burden or side effects of a dual treatment of TB and HIV affect the adherence to 
medication intake and consequently the TSR (Gebremariam et al. 2010). Guinea is a 
country with a generalized HIV epidemic, but a low HIV prevalence of 1.4% in adults 
(UNAIDS 2019). The country has poorer HIV-related performance indicators than 
most high-prevalence Southern African countries. Country-wide indicators regarding 
the percentage of patients who know their HIV diagnosis, who are on ART and who 
are virally suppressed are unknown. Accentuated by the rural surroundings in the 
Forest Region, HIV diagnosis is often not considered and therefore missed at earlier 
stages. Also, according to the UNAIDS report 2019, Guinea is a country with a very 
high level of stigma towards PLWH, whereby approximately 70% of people 
responded they would not buy vegetables from a shopkeeper known to be living with 
HIV. All these factors additionally contribute to delayed health-seeking behavior and 
delayed detection of HIV or TB through the health care system. We therefore argue 
that our figures with a markedly lower TSR in PLWH (61.2% for those already on 
ART and 53.6% for those not yet on ART) represent a realistic capture of the 
mentioned difficulties for people co-infected with HIV-TB and living in rural Guinea.  
In the context of sub-Sahara Africa, our results are comparable regarding the factors 
associated with a poor treatment success. The significant influence of TB-HIV co-
infection on poor treatment success of ATT is shown in several studies from sub- 
Saharan Africa (Gabida et al. 2015; Oshi et al. 2015; Asres et al. 2016; Zenebe and 
Tefera 2016). Different studies from Ethiopia and Nigeria show, that especially lack of 











success (Ige and Oladokun 2011; Tadesse et al. 2013; Ofoegbu and Odume 2015; 
Gebrezgabiher et al. 2016; Zenebe and Tefera 2016; Woimo et al. 2017). The range 
of treatment success varies a lot between the countries and regions in sub-Saharan 
Africa. A systematic review and meta-analysis (covering studies from 7 countries) 
over the years 2008-2018 showed a TSR of 76.2% among bacteriologically 
confirmed PTB cases, which is comparable to our TSR of 78.2% (Izudi et al. 2019). 
This study has some limitations. It is based on data from a single reference hospital 
with local circumstances that may have had an impact on data quality: data handling 
errors occurred due to transcription from paper-based national TB program ledgers to 
the electronic register, and different reporting requirements by the Ministry of Health 
over these eight years complicated the adjustment of the data. Another weakness, 
the lack of resources and the difficult logistical setting of the CHRS (2 days travel 
away from the capital with unsealed access roads) is illustrated in the late 
introduction of GeneXpert based molecular testing of MDR/RR-TB cases. As a well-
known difficulty in resource-poor settings, limited diagnostic possibilities result in a 
certain number of false positive TB diagnoses, e.g., any severe chronic lung illness 
(potentially cancer or fibrosis etc.) will be primarily attributed to TB. This will explain 
the lower TSR in non-microbiologically confirmed TB. A systematic limitation is given 
by the pre-defined WHO definitions, resulting in a larger number of patients with the 
outcome “not evaluated” because patients transferred-out are assigned to this 
category.  
The main strength of the study is the center’s function as one of the two national 
reference centers for TB and the one not situated in the capital city. Its importance in 
the Forest Region, resulting in a high number of PLTB arriving from outside the 











eastern part of the country. This study is the first publication of TB data in Guinea 
outside the aggregated national data, which enables an independent view on the 
situation of the Forest Region of Guinea. Another strength of the study is the 
improvement in TSR over these eight years due to better care for people with TB-HIV 
co-infection, shown in a higher HIV testing rate (89%) compared to the 81% in the 
national data and an increase of PLWH on ART from 20% in 2010 up to 81.2% in 
2017. Furthermore, a higher treatment success over these eight years could be 
reached due to the decrease of 3.4% in deaths, despite fewer bacteriologically 
confirmed TB cases.  
Conclusion 
Despite marked improvement of treatment success over the eight years depicted in 
this analysis, we showed that the target TSR of 90% could not be reached, due to 
high early mortality and an increase of LTFU in later treatment months. Advanced 
age, long travel distances to the hospital, a positive HIV status and late drug refill 
were associated with lower treatment success. However, the increase of the TSR 
over the years shows a positive evolution of the tuberculosis program of the CHRS. 
The more systematic patient recall and reminder system that is planned has the 
potential to reduce delays of drug refill at month two or three. Furthermore, closer 
collaboration with the local medical centers that supervise a part of the treatment for 
PLTB outside of Macenta could result in a better treatment surveillance and thus in a 
better treatment success with fewer costs and time requirements for patients. Finally, 
further improvements in TB diagnostics, starting with a wider use of the GeneXpert 
platform, will enable a more certain exclusion of non-TB cases and thus hopefully a 
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Figure 1: Flow diagram showing the numbers of participants at each stage. 
Legend figure1: TB – tuberculosis, PTB – pulmonary TB, LTFU – loss to follow up, 













Figure 2: Evolution of the treatment success rate 2010 - 2017 
Legend figure2: Treatment success rate, defined as the sum of categories “cured” or 
“treatment completed” in people diagnosed with drug susceptible tuberculosis, shown 
for all patients grouped by year of registration. The shaded bars show treatment 
success, while the filled bars show treatment outcomes with no treatment success.  













Figure 3: Overall treatment success rate and stratified according to history of 
previous anti-tuberculosis treatment 
Legend figure3: Treatment success rate, defined as the sum of “cured” or “treatment 
completed”, in people diagnosed with drug susceptible tuberculosis, shown for all 
patients, incident cases (new and relapse cases) and all other retreated patients (all 
retreated cases except “retreatment after relapse”). The shaded bars show treatment 
success, while the filled bars show treatment outcomes with no treatment success.  












Figure 4: Treatment success rate according to HIV status 
Legend figure 4: Treatment success rate, defined as the sum of “cured” or “treatment 
completed” in people diagnosed with drug susceptible TB, and shown for people not 
living with HIV versus people living with HIV on ART and not on ART at start of anti-











treatment outcomes with no treatment success. Percentages indicate treatment 
success rate. TB – tuberculosis, ART – antiretroviral therapy 
 
 
Figure 5: Treatment success rate according to bacteriologically confirmed or clinically 
diagnosed TB cases  
Legend figure 5: Treatment success rate, defined as the sum of “cured” or “treatment 
completed” in people diagnosed with drug susceptible TB, and shown for 











treatment success, while the filled bars show treatment outcomes with no treatment 
success. Percentages indicate treatment success rate. TB – tuberculosis 
 
 
Figure 6: Crude and adjusted odds ratio (95% confidence interval and p-value) from 
logistic regression analysis identifying factors associated with treatment success in 
new and relapse TB cases  
Legend figure 6: Logistic regression for crude and adjusted odds ratio. OR – odds 
ratio, CI – confidence interval, TB – tuberculosis; CHRS - Centre Hospitalier Régional 
Spécialisé in Macenta; ART - antiretroviral therapy, Ebola - months of the main 
epidemic Ebola period in Macenta (August - December 2014); year of anti-TB 
treatment start refers to the years 2010-2017, the OR is given per later year of 
registration and compared to the respective previous year, for example treatment 
success of 2011 compared to 2010 and treatment success of 2012 compared to 











Table 1: Patient demographics, including all patients diagnosed with a drug susceptible 


































34 (25 - 46)  
max. 99 
 
34 (24 - 45) 
max. 91 
 
37 (27 - 49)  
max. 99 
<0.001 
Age categories (%) 



































































Place of residence (%) 
Macenta town 
Guinea, distance to CHRS ≤ 100km 

























Distance from home to clinic (km) 
median (IQR)a, maximum b 
 
127  
(58 - 350) 
max. 989 
127  
(58 - 302) 
max. 989 
133  
(80 - 350) 
max. 732 
<0.001 
Percentages may not total 100 due to rounding.  
a IQR – interquartile range; b excluding patients from Macenta town, foreign nationals and 
unknown. As a measure of the distance, we calculated the kilometers by road, using Google 













Table 2: Tuberculosis characteristics and HIV status at inclusion in TB program and diagnosed 










Treatment category (%) 
1st line – initial regimen 















Treatment history (%) 
New patients* 
Retreatment all* 
--- retreatment after relapse  
--- retreatment after loss to    
     follow-up 
--- retreatment after failure 






--- 124 (3.1) 
--- 46 (1.2) 
 
--- 76 (1.9) 






--- 94 (3.1) 
--- 35 (1.2) 
 
--- 51 (1.7) 






--- 30 (3.1) 
--- 11 (1.1) 
 
--- 25 (2.6) 




Type of tuberculosis disease (%) 
Bacteriologically confirmed 
pulmonary tuberculosis 















































HIV status (%) 
HIV positive 
HIV negative 
unknown (not tested and missing) 
 
 















HIV positive (%) 
on ARTd 









HIV type (%)e  
HIV-1 infected 
HIV-2 infected 
















c retreatment regimen: tuberculosis treatment regimen with the addition of streptomycin and 
prolonged for 8 months (2HRZES/1HRZE/5HRE) d ART – antiretroviral therapy e HIV positive 
only. * the p-value refers to the major categories labeled with an asterisk. CHRS – “Centre 
Hospitalier Régional Spécialisé” 
Percentages may not total 100 due to rounding. 
 
 
Jo
ur
na
l P
re
-p
ro
of
